Abstract:AbstractBackgroundRecent studies have shown that almost half of patients with Alzheimer’s disease demonstrate signs of epileptic activity as measured with EEG. Subclinical epileptic discharges can disrupt network activity, which is critical for long term memory. Therefore, suppressing epileptiform discharges may represent a novel therapeutic target for patients with Alzheimer’s disease. In the current randomized controlled trial, we recruited patients with mild Alzheimer’s disease and investigated the effect of a single administration of 2.5 mg/kg or 7.5 mg/kg of levetiracetam as compared with placebo on cerebral blood flow as measured with arterial spin‐labeling MRI (ASL‐MRI).MethodWe conducted a double‐blind, within‐subject crossover study in which nine participants with mild Alzheimer’s disease received placebo, 2.5 mg/kg, and 7.5 mg/kg of LEV intravenously in a randomized order across three sessions. Afterwards, participants underwent ASL‐MRI and performed a variety of neuropsychological cognitive tests. The regions with significant perfusion changes were analyzed with Statistical nonParametric Mapping (SnPM) toolbox.ResultWhen comparing 2.5 mg/kg levetiracetam with placebo, we found significant (p<0.03 with family wise error corrected at a level of 0.05) increases in relative cerebral blood flow in a cluster involving both temporal lobes, including the hippocampus, with greater involvement on the left side. We found decreases in a cluster including the posterior cingulate cortex and precuneus. No clear changes were found following the higher dose. No significant differences in cognitive performance were found between the three groups, suggesting that the intervention neither worsened nor improved cognition.ConclusionIn the current study, we found that in mild Alzheimer’s disease patients without any history of epilepsy a low dose of levetiracetam leads to changes in the cerebral blood flow in areas known to be affected early in the disease. One possible explanation could be that in mild AD, epileptic activity in the hippocampus leads to an excessive inhibition, and so relieving the inhibition with levetiracetam leads to an increased blood flow. These findings provide evidence of a potential beneficial effect of levetiracetam in patients with Alzheimer’s disease, but larger studies are needed, particularly with longer dosage schedules to determine whether there are any clinical improvements.

Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Effect of levetiracetam in benign childhood epilepsy with centro-temporal spikes:a resting-state fMRI study based on amplitude of low frequence fluctuation

Evaluation of levetiracetam on the gray matter structure remodeling in benign epilepsy children with-central temporal spikes

Single-dose Intravenous Administration of Antiepileptic Drugs Induces Rapid and Reversible Remodeling in the Brain: Evidence from a Voxel-Based Morphometry Evaluation of Valproate and Levetiracetam in Rhesus Monkeys

Evaluation of Levetiracetam and Valproic Acid As Low-Dose Monotherapies for Children with Typical Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS).

Antiepileptic Drug of Levetiracetam Decreases Centrotemporal Spike-Associated Activation in Rolandic Epilepsy

Anti-Seizure Medication Treatment of Benign Childhood Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis

Less efficacy of valproic acid monotherapy may be caused by neural excitatory rebound in seizures

Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis

Treatment for the Benign Childhood Epilepsy With Centrotemporal Spikes: A Monocentric Study

Effects of Carbamazepine and Lamotrigine on Functional Magnetic Resonance Imaging Cognitive Networks

Effect of Antiseizure Medication on the Salience Network in Patients with Epilepsy with Generalized Tonic-Clonic Seizures Alone

The Influence of Carbamazepine,Valproate and Topiramate on the Cognitive Function Related to the Frontal Lobe among the Newly Diagnosed Partial Epilepsy

Single curative effect of three antiepileptic drugs on untreated children with benign childhood epilepsy with centro-temporal spikes

Levetiracetam Increases Hippocampal Blood Flow in Alzheimer’s Disease As Measured by Arterial Spin Labelling MRI

Efficacy and safety of levetiracetam versus valproate in patients with established status epilepticus: A systematic review and meta-analysis

Regional homogeneity (ReHo) changes in new onset versus chronic benign epilepsy of childhood with centrotemporal spikes (BECTS): A resting state fMRI study

Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects

Resting state signal latency assesses the propagation of intrinsic activations and estimates anti-epileptic effect of levetiracetam in Rolandic epilepsy

Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats